Cobro Ventures

Cobro Ventures

Cobro Ventures

Follow us
Pulse 2.0

C4 Therapeutics (CCCC) Stock: $15 Price Target From BofA

Forbes

Dyslexic To Disruptor: Frequency Therapeutics CEO David Lucchino Is Working To Reverse Hearing Loss

$150,000,000 Venture capital (Series B)
FinSMEs , Pulse 2.0

C4 Therapeutics Raises $170M in Funding

$30,000,000 Venture capital (Series A)
FinSMEs , Xconomy

Regenacy Pharmaceuticals Secures $30M in Series A Financing

Xconomy

Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds

$42,000,000 Venture capital (Series B)
PE HUB , FinSMEs

Frequency Therapeutics scores $42 mln Series B

$32,000,000 Venture capital (Series A)
PE HUB

Frequency Therapeutics takes in $32 mln Series A

Funding Messaging
$73,000,000 Venture capital (Series A)
FinSMEs

C4 Therapeutics Closes $73M Series A Financing

Science Health Funding